CordenPharma has announced the acquisition of AmbioPharm. The deal is intended to expand CordenPharma's global capacity for the production of peptide Active Pharmaceutical Ingredients (APIs).
AmbioPharm specializes in the development and manufacturing of peptide APIs. The acquisition will integrate AmbioPharm's operations and expertise into CordenPharma's existing network. Further details regarding the financial terms of the acquisition were not immediately disclosed.
This transaction represents a consolidation within the pharmaceutical ingredients sector. The combined entity aims to leverage the strengths of both companies to serve the market more effectively.
